Business Data Enrichment Services
FDA · FDA OFFICE OF ACQ GRANT SVCS
FDA is planning to buy "Business Data Enrichment Services". This is an early notice: it is not taking bids yet. The work is in Silver Spring, MD, USA. The original due date (Nov 15, 2024) has passed; check the latest amendment for the current one. In the last 2 years, similar work (matched on the agency only, a loose match) went to 10 or more companies, usually for about $2.6M per award.
Put together from the facts on this page; the details and sources are below.
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation FDA-RFI-75F40125Q00020 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The purpose of this request for information is to obtain technical and/or business information and input from the marketplace for project planning purposes regarding the availability of existing or potential solutions, pursuant to FAR Part 10 Market Research, to identify potential parties from the marketplace capable of providing Business Data Enrichment Services to implement an enterprise master data management program to improve the completeness and accuracy of existing and incoming data, and ensure all business data are accurate, consistent, and fit for purpose across operational and analyt… (show all)
ical systems that interact with the Agency. This goal is accomplishable through a multi-tiered approach aimed at prioritized and focused components of enterprise data management and enterprise data interoperability. This is a REQUEST FOR INFORMATION ONLY, not a Request for Quote (RFQ). The RFI does not commit the Government to award a contract now or in the future for any supply or services whatsoever. Furthermore, the FDA will not accept unsolicited proposals. The Government is not responsible for any cost incurred by stakeholders in furnishing information. All costs (time/material/services) associated with responding to this RFI will be solely at the interested stakeholder's expense. Not responding to this RFI does not preclude participation in any future RFI, Vendor Day, or RFQ, if any are issued. Any information submitted by stakeholders to this RFI is strictly voluntary. All submissions will become Government property and will not be returned. The Government reserves the right to request clarifying remarks from RFI submissions. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Federal Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). The FDA will use the results of the market research to determine if sources capable of satisfying the agency's requirements exist based on its response to the questions contained in this notice. The FDA does not intend to make a selection decision or award a contract on the basis of responses. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the outcome of the FDA's review of the information received. Additionally, the FDA does not intend to hold discussions concerning this RFI with any interested parties. However, FDA reserves the right to contact vendors if additional information is required.
Recent Agency Awards (Loose Match)
24 award notices on SAM.gov in the last 24 months. Matched by: Same agency (FDA), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (24): middle half $402K to $19.1M, median $2.6M; range $82K to $120.8M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| Please_See_Spreadsheet Silver Spring MD 20993 USA | 3 | $153.2M | Oct 8, 2026 |
| DCT, INCORPORATED | 1 | $52.8M | Sep 15, 2026 |
| TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC | 1 | $50.0M | Sep 16, 2025 |
| NATI-NVE Support Services, LLC | 1 | $49.0M | May 21, 2026 |
| HARVARD PILGRIM HEALTH CARE INC | 1 | $31.7M | Mar 30, 2026 |
| TOXICOLOGIC PATHOLOGY ASSOCIATES INC | 1 | $26.1M | Sep 15, 2025 |
| IHRC, INCORPORATED | 1 | $14.5M | Sep 16, 2026 |
| VITALANT Scottsdale AZ 85258 USA | 1 | $10.0M | Sep 8, 2025 |
| WE PHARMA, INC. | 1 | $4.0M | Sep 11, 2026 |
| THE BIONETICS CORP | 1 | $2.8M | Jul 21, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- Oct 8, 2026Please_See_Spreadsheet Silver Spring MD 20993 USA$120.8MFY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Sep 24, 2026TRADESPACE INC$82KPlatform Subscription to Support Transfer Program Commercial Assessment LeadsNo listed company matched (Materiality N/A)
- Sep 24, 2026TURBOFIL PACKAGING MACHINES, LLC$454KAutomated Vial Capper Machine and Labeler systemNo listed company matched (Materiality N/A)
- Sep 22, 2026ABIDE INTERNATIONAL, INC.$1.8MBuilding Exterior Repair Project � FDA Pacific Southwest LaboratoryNo listed company matched (Materiality N/A)
- Sep 17, 2026LUSARDI CONSTRUCTION CO. San Marcos CA 92078 USA$779KIRV Exhaust and Vacuum Pump ReplacementNo listed company matched (Materiality N/A)
- Sep 16, 2026IHRC, INCORPORATED$14.5MFDA Occupational Safety, Industrial Hygiene, Information Systems, and Training (OSIST) IDIQNo listed company matched (Materiality N/A)
- Sep 15, 2026DCT, INCORPORATED$52.8MNational Center for Toxicological Research (NCTR) on-site facility Operations and Maintenance (O&M) support servicesNo listed company matched (Materiality N/A)
- Sep 11, 2026WE PHARMA, INC.$4.0MPharmaceutical Products for CDER Research Studies - IDIQNo listed company matched (Materiality N/A)
- Aug 31, 2026GOVERNMENT SCIENTIFIC SOURCE INC$399KDigital Slide Scanner SystemNo listed company matched (Materiality N/A)
- Aug 21, 2026Z-SPEC, INC.$123KPost-Award Public NoticeNo listed company matched (Materiality N/A)
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Food & Drug Administration (FDA) since 2024 (0 filings)
- 0 of their lobbyists list a past Food & Drug Administration (FDA) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 131 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.